District Court Orders New Trial on Damages In Light of Virnetx, Inc. v. Cisco Systems, Inc.

Dec 1, 2014

Reading Time : 2 min

At trial, Plaintiff Power Integrations, Inc.’s damages expert, Mr. Putnam, provided a damages opinion for the jury based on the expected harm of Fairchild’s infringement. In doing so, Mr. Putnam testified that “[i]f you have got competitors where the sale of the product causes the patentee to lose something . . . you don’t apportion [damages to only the patented features].”

Apportionment Requirement for Patent Damages

It has been a longstanding requirement that a patentee “must in every case give evidence tending to separate or apportion the defendant’s profits and the patentee’s damages between the patented feature and the unpatented features . . . [or] that the profits and damages are to be calculated on the whole machine, for the reason that the entire value of the whole machine, as a marketable article, is properly and legally attributable to the patented feature.” Garretson v. Clark, 111 U.S. 120, 121 (1884).  Subsequent Federal Circuit precedent has provided further instructions on calculating damages in technical cases where claims are drawn on an individual component of a multi­component product and, when using a “royalty base claim encompassing a product with significant non­infringing components,” the patentee should identify and bases its damages on “the smallest salable infringing unit with close relation to the claimed invention.” See Virnetx, Inc. v. Cisco Sys., Inc., 767 F.3d 1308, 1327 (Fed. Cir. 2014) (quoting Cornell Univ. v. Hewlett­Packard Co., 609 F. Supp. 2d 279, 285 (N.D.N.Y. 2009)).

In VirnetX, the Federal Circuit provided additional clarification on when apportionment must occur. VirnetX’s damage expert had claimed to identify the smallest salable infringing unit and calculated a royalty based on that identification. See id. at 1325­26. On appeal, Cisco Systems, Inc. argued that the lower court’s jury instruction, which stated “In determining a royalty base, you should not use the value of the entire apparatus or product unless . . . the product in question constitutes the smallest salable unit containing the patented feature,” improperly suggested that when using a smallest scalable infringing unit, no further apportionment is needed. See id. at 1327. The Federal Circuit agreed, and held that the patentee must in all cases apportion between the patented and unpatented features. Even where a patentee identifies the smallest salable infringing unit, “the patentee must do more to estimate what portion of the value of that product is attributable to the patented technology.” See id. at 1327­28.

The VirnetX Opinion Required District Court to Reconsider Its Opinion

The court found that the Federal Circuit’s opinion in VirnetX provided a clarification that represented a material difference in law from that which was presented to the court and, therefore, Fairchild had shown good cause for reconsideration. Next, the court reviewed the testimony of Mr. Putnam, who disclaimed reliance on the entire market value rule, and focused on a royalty based on expected harm. Despite Power Integrations’ argument that VirnetX did not require apportionment on its expected harm theory, the court held that VirnetX mandated a new trial on damages. The court noted the “Federal Circuit’s clear directive [in VirnetX] that no matter what the form of the royalty, a patentee must take care to seek only those damages attributable to the infringing features.” Because Mr. Putnam’s analysis did not undertake any apportionment, the court concluded that the prior jury lacked sufficient evidence upon which to base its damages award and, consequently, a new trial on damages is required.

Power Integrations, Inc. v. Fairchild Semiconductor International, Inc. (N.D. Cal.) (Nov. 25 Order).

Share This Insight

Categories

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.